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Change alone is eternal, perpetual, immortal
Arthur Schopenhauer
Good judgment comes from experience
and experience comes from bad judgment
The article outlines the main principles of randomized clinical trials (RCTs) and discusses various problems related 
to their organization and performance. RCTs constitute a golden standard in medical literature, including surgical 
journals, but when badly constructed and conducted, they might cause more harm than good. The chief difficulties 
involved in organizing RCTs include the appropriate selection of patients, correct randomization, serious ethical 
concerns, and considerable cost. Their presence is attested to by the negligible number of RCTs, which only represent 
as few as 3 to 7% of all surgical studies. Cancer surgery is often radical and irreversible and requires respect for the 
preferences of patients and surgeons. It is not a lab experiment where everything can be neatly planned and car-
ried out. In RCTs, study groups differ in terms of one variable. Cancer surgery, on the other hand, needs to take into 
account many different variables describing the patient, the disease, and the surgeon at the same time. The results 
of randomized studies cannot be applied across the board, even for patients who suffer from the same cancer. The 
findings are true only for the group of patients who participate in the study and their generalization to the whole 
patient population raises a serious objection.
There is a great need for clinical studies in cancer surgery, no matter whether they are randomized or not. Large, 
prospective, multi-center cohort studies, well-kept cancer registries, retrospective studies, and clinical case series 
furnish a very useful and precious source of knowledge. Expert consensus conferences are particularly valuable in 
practical terms. In recent years, there has been increasing pressure on reference centers from the medical industry 
and business to perform randomized trials. Studies of this kind, especially when published in high-impact journals, 
play an important role in introducing new equipment, methods, and drugs to clinical practice.
This causes a reasonable objection. Something must be “afoot” if all studies are currently required to feature a conflict-
of-interests (COI) formula. To sum up, cancer surgery needs scientific studies, but not necessarily only RCTs. The author 
is against the overemphasis on randomized trials and the impact factor in clinical practice.
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Introduction
Until recently, doctors would treat their patients “ac-
cording to their best knowledge and conscience”. Article 
4 of the Medical Code of Ethics stipulates that “in execution 
of his/her duties the physician must be free to proceed 
in accordance with his/her conscience and to undertake 
professional activities in accordance with contemporary 
medical knowledge”.
Today, we rely on available economic and technologi-
cal solutions, treatment benefits, clinical wisdom, common 
sense, prudence, and above all, human empathy and the 
good of the patient. In this context, it is difficult to conduct 
randomized clinical trials and one may even ask whether 
they are necessary at all [1].
Cancer surgery usually causes an irreversible clinical 
change. Thus, creating placebo control groups raises serious 
ethical reservations. In a randomized trial, we may operate 
on a group of patients and get a negative; the trial will be 
stopped, of course, but who will be accountable to patients 
who already suffer from serious complications? Are we going 
to say that whatever happened, happened for the sake of 
science, at the service of evidence-based medicine?
 “Prospective, randomized, double-blind, placebo-con-
trolled trials” are now the magic formula for some physi-
cians. The evidence and knowledge obtained through such 
studies have been expected to furnish the basis for clinical 
proceedings for the past 20 years or so, or at least this is what 
scientists claim. In 1996, R. Horton, editor-in-chief of the 
Lancet, wrote “Only when the quality of publications in the 
surgical literature has improved will surgeons reasonably be 
able to rebut the charge that as much as half of the research 
they undertake is misconceived” [2]. D.L. Sackett, the pioneer 
of evidence-based medicine, stated that: “As physicians, 
whether serving individual patients or populations, we have 
always sought to base our decisions and actions on the best 
possible evidence” [3]. The best possible evidence comes 
from prospective, randomized, placebo-controlled studies; 
these should also inform decisions in surgery, which often 
has irreversible consequences.
In cancer surgery, RCTs should not be conducted if par-
ticipants cannot be ensured the top standard of treatment 
in terms of organization, methodology, funding, follow-up, 
and patient survival rates, as well as adequate handling of 
possible complications. Neither are they a good choice if 
important implications from stage 1 and 2 trials, ethical, 
medical, statistical or other factors fail to justify the need 
for a randomized study.
Before conducting an RCT, it is worth asking: cui bono? 
Is the good of the patient really a priority for the medical 
institution that organizes and funds the study? Will we be 
able to track patients in the follow-up to the trial? The chief 
elements to consider include:
 — reduced mortality rate;
 — increased average survival rate;
 — increased five-year survival rate;
 — improved quality of life;
 — improved cost/effect ratio, e.g. the cost of one-year 
survival. 
Even though thoroughly planned and well-conducted 
RCTs provide the most precise and reliable information, they 
are still quite rare in cancer surgery. A survey of literature 
published in the 1990s indicated that they accounted for 
as few as 7% of all trials performed in the field [4]. In 2003, 
experts assessed that only 3.4% of studies published in 
leading surgical journals involved RCTs [5]. In addition, only 
44.1% of RCTs compared and contrasted different surgical 
methods, while 55.9% focused exclusively on conservative 
treatment [5].
In 1985, 14% of all studies published in the British Journal 
of Surgery were randomized; seven years later, the figure 
dropped to just 5% [6]. There are many methodological and 
organizational reasons for this decrease. The main obstacle 
to such trials is the clear preference of surgeons and patients 
for specific methods [4]. Lack of funding and patient pref-
erences were identified as the most important barriers to 
RCTs by a group of Australian surgeons [7]. Another study 
estimated that only around 45% of patients who met the 
qualification criteria agreed to take part in the study, while 
42% of colorectal cancer patients preferred one of the stud-
ied surgical methods [8].
Difficulties are posed not only by the preferences of 
patients, but also those of surgeons. A concept of com-
munity equipoise was introduced to evaluate discrepancies 
in expert opinions, preferences, and assessment of new 
methods; the idea refers to the homogenization of beliefs, 
i.e. a community equilibrium among experts that makes ran-
domized studies possible. In many surgical cases, there is no 
data from randomized clinical trials and the best treatment 
is chosen on the basis of clinical guidelines that take pa-
tient preferences into account. For instance, doctors opt for 
a less radical and invasive method that ensures a potentially 
lower survival rate, but a better quality of life. The decision 
is consulted with the patient.
It is possible to evaluate the preferences of the surgeon 
community, e.g. during conferences attended by experts 
who decide on specific recommendations. Such consensus 
relies not only on the knowledge obtained through RCTs 
but also the preferences of surgeons that are rooted in 
their experience.
Why should we conduct randomized trials? 
RCTs originated as a prevalent phenomenon in the last 
decades of the 20th century. Previously, clinicians based 
their decisions on observations carried out over many years, 
as well as the observed efficacy of specific methods. Many 
treatments, such as insulin, vaccinations, or appendectomy 
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in acute appendicitis, do not require randomized trials. No-
body expects clinical studies to be conducted where effec-
tive treatments are already available. 
Certain modifications in cancer surgery slightly improve 
treatment results and raise the quality of life, but is that 
reason enough to organize difficult and costly randomized 
trials that take years and years to complete? Informed by 
the fashion for EBM, we now accept that RCTs are the most 
valuable source of knowledge, but we also need to recog-
nize their flaws and difficulties. They are time-consuming 
in terms of planning, patient selection, performance, and 
monitoring. Their findings cannot be generalized and uni-
versally applied since they are true for a small group selected 
in accordance with specific eligibility criteria. Whenever 
a rare disease is investigated or desired results show up only 
after a long time, RCTs are not possible.
Randomized trials are also controversial for ethical rea-
sons. How can surgeons possibly accept randomization 
knowing that one of the studied treatment methods might 
be better than the other, even if that belief is founded on 
untested, anecdotal evidence?
Methodological problems are of great concern as well, 
especially in surgery. How should we go about evaluating 
the learning curve for a new treatment, whose efficacy we 
want to test against an existing method? Surgeons need to 
achieve mastery in a new technique before they can begin 
to recruit patients. And what is the situation like today? 
A new method appears, and before we even know how to 
use it, a company that produces relevant surgical equipment 
suggests a randomized clinical trial should be conducted.
In order to reduce systemic errors, careful attention 
should be paid to choosing the randomization method, al-
location concealment, and properly blinding the study. In 
surgical studies, blinding is very difficult, especially for the 
surgeon. For instance, when we compare laparoscopic and 
traditional procedures, the cat is let out of the bag at the 
first dressing of the wound. In order to properly carry out 
a RCT, a sham operation needs to be performed in the control 
group, which raises serious ethical concerns and may cause 
health complications, etc. The blinding process should no 
doubt cover patients, the personnel who collects patient 
data, administrative staff, and all those responsible for fund-
ing and results analysis. If this is not possible, RCTs should not 
be conducted. The good of the patient should be taken into 
account in terms of treatment intentions; it is crucial to draw 
up and carry out a detailed and complete follow-up program 
and strive to minimize statistical error by defining the precise 
size of studied patient groups (power analysis) [9].
The greatest problems with RCTs  
are related to patients 
Surgical procedures are irreversible. We know, for in-
stance, that in rectal cancer, lower anterior resection is con-
sidered superior to abdominal-sacral incision, because it 
does not end in a definitive stoma. However, some authors 
point out that anterior resection involves a higher rate of 
relapse. How can we persuade patients to take part in the 
study, knowing that they may be assigned to a group that 
undergoes a definitive stoma, if it could be avoided if they 
ended up in the group treated by means of anterior resec-
tion [10]? 
Another reason for such a small number of RCTs in can-
cer surgery is the lack of legal regulations concerning rand-
omized trials in many countries. There are few institutions 
such as the US Food and Drug Administration or the Cana-
dian Health Protection Branch that would oversee clinical 
drug trials. Clinicians introduce new surgical methods with 
a certain apprehension and many restrictions even before 
their local ethics committees. A good example of this lack 
of control was the “explosion” of laparoscopic techniques 
that occurred both in general and cancer surgery without 
any preliminary controlled studies. Most surgeons simply 
jumped on the bandwagon, because they were new, faster, 
and more cost-effective.
All these factors do not make an exhaustive list of the 
issues and difficulties that make surgeons look at RCTs with 
a certain reserve. Most prefer to rely on the results of large 
long-term observational studies. Randomized clinical trial 
results available in cancer surgery are few and far between 
and their statistical quality is low, estimated at 0.4 on a scale 
from 0 to 1 [11]. What we should do instead, therefore, is look 
for prospective, pragmatically well-controlled comparative 
and observational studies [9]. Their informational value is 
far greater than that of badly planned and conducted RCTs. 
In 1996, T. Quill published an alarming article discussing 
how the responsibility for medical procedures has been 
increasingly moved from the physician to the patient in the 
ostensible interest of the autonomy of the latter [12]. There 
is a serious clash between the huge store of knowledge pos-
sessed by the physician and the expectations of patients, 
whose grasp of medicine is at best negligible. The old ques-
tion thus comes up again: what should matter more in clini-
cal decision-making — the will or the good of the patient?
Surgeons do not need to live with the 
consequences of treatment — patients and 
families do
Table I presents two alternative scenarios for clinical 
medical proceedings: A. evidence-based medicine, B. prefer-
ence-based medicine.
Both scenarios help establish a relationship between 
the doctor and the patient that works best for the latter. 
The doctor is an expert on medicine, patients and their rela-
tives are experts on patient preferences and expectations. 
Preference-based medicine thus relies on the evidence they 
provide regarding the reality and objectives of treatment, its 
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benefits, burdens, and patient’s abilities (there is no room for 
those variables in RCTs). Patients, families, and doctors must 
arrive at a consensus concerning the method of treatment. 
The likelihood of a cure should not be exaggerated; nor 
should the patient be scared with possible complications. It 
is necessary to put aside enough time for conversation [13].
Clinical trials can be divided into several groups depend-
ing on their statistical power (Tab. II). Ellis et al. distinguished 
three types of evidence:
 — evidence from randomized clinical trials;
 — evidence from non-randomized, prospective studies 
and large retrospective studies;
 — surgical interventions based on descriptions of clinical 
cases or results of small clinical trials. 
Only 25% of surgical patients received treatment based 
on evidence from group 1 [14]. A group of cardiothoracic 
surgeons who evaluated 50 different procedures reported 
that only 14% were based on trials from group 1, and 64% 
— group 2 [5]. More than 80% of all published surgical 
studies still rely on clinical case studies or small case series 
from isolated centers. 
RCTs are a golden standard today but we must also be 
aware of the difficulties that they pose in terms of construc-
tion and performance in order to make sure that they are 
really worthwhile and reliable. Otherwise they are bound 
to do more harm than good. Even if RCTs are conducted, 
however, the practical implementation of their results will 
engender another set of problems. The best example are the 
reports and metaanalyses published by the Cochrane Col-
laboration, an institution that has now become a platform 
for publishing top-quality scientific evidence [5].
RCTs have a theoretical advantage over other types of clini-
cal studies, but experimental studies that compare treatment 
results observed in randomized and non-randomized trials of-
ten fail to confirm their superiority, so their obvious (axiomatic) 
importance cannot be accepted blindly. Small, ill-constructed 
randomized trials give false results and may do much harm [6]. 
56% of RCTs are reported to suffer from serious methodological 
errors, and only 58% are correctly randomized [15].
The history of medicine does not lend support to the 
statement that only randomized controlled clinical trials can 
lead to progress in surgery. Once anesthesia and antiseptic 
drugs were developed, many excellent surgical treatment 
methods appeared, including those targeted at cancer pa-
tients. Many surgeries performed today were introduced 
long before the advent of randomized trials.
Cancer surgery should rely on so called feasibility studies, 
i.e. the assessment of the feasibility of a new surgical method 
or a modification of an existing technique. Such studies al-
low to compare, for instance, between manual and stapled 
colorectal anastomosis. 
The vagaries of evidence-based medicine are discussed 
by Winek et al., authors of a very interesting study that 
encourages deep reflection on the subject [16]. Its final 
sentence has a particularly strong resonance for me: “Even 
though contemporary medicine is based on facts, it still 
remains an art”.
Conclusions
In 2015, the European Colorectal Surgery Congress in 
St. Gallen featured a panel session devoted to scientific 
studies in cancer surgery. There has been some fatigue 
with evidence-based medicine and the exaggerated weight 
given to RCTs. More and more emphasis is currently placed 
Table I. A balanced approach to achieving the goal — targeted patient care
Evidence-based medicine Preference-based medicine
1. Defining and asking the right question 1. Designing and holding an interview with the patient and the family 
2. Finding evidence necessary to solve the problem 2. Getting the patient and the family to articulate their preferences, 
discussing the goal of treatment, presenting the doctor’s experience 
in non-scientific language
3. Critically evaluating the evidence 3. De-biasing and preventing emotional reactions 
4. Taking a decision 4. Creating recommendations and looking for consensus (combined 
with EBM evidence).
5. Assessing feasibility and effectiveness 5. Ensuring continuing care and follow-up
Table II. Levels of evidence used in clinical medicine (website: NHS 
Research and Development — Center for Evidence-based Medicine)
Level Evidence from:
1a systematic review of RCTs 
1b at least one randomized trial
1c all-or-none case series
2a systematic review of cohort studies
2b at least one cohort study
2c at least one ecological study or “outcomes research”
3a systematic review of “case-control” studies
3b individual “case-control” study
4 case series
5 expert opinion
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on the importance of well-kept national disease registries 
and large observational studies.
Success in cancer surgery does not depend on this or 
that randomized study. In my opinion, it has more to do 
with patient factors (age, co-morbidities, nutrition, etc.), 
cancer-related determinants, especially its progression, sur-
geon characteristics (skill, experience, personality), available 
technology, and the possibility of combined treatment.
One more thing: medicine is gradually being taken over 
by the law of material value. Practical assessments of treat-
ment profitability are being tolerated today and a price tag 
is increasingly put on human life. Doctors are instructed to 
take decisions based on economic factors. Let us remem-
ber that medical economism is immoral, and morality is 
a categorical and ultimate value that also science should 
respect. Moral concerns may be hidden from scientific and 
biological studies, which is why the language of science 
avoids concepts such as morality and conscience, but we still 
have a valid code of ethics. Ethics and morality are especially 
important when planning and conducting scientific studies. 
There has been a dynamic growth in technology and basic 
sciences in medicine. Business and industry have caught 
on to the opportunity of making large profits under the 
banner of care and the good of the patient. Business has 
repeatedly attempted to influence scientific studies, which 
is why many trials, especially RCTs, feature an abbreviated 
formula COI — conflict of interest, as well as disclosure state-
ments, sources of funding, etc. Something is afoot after all! 
Are randomized clinical trials needed  
in cancer surgery? 
Yes, but only on the condition that they are correctly 
planned and conducted. Randomized trials should not 
crowd out cohort studies, observational, prospective, and 
retrospective studies. “Science limits itself to stating the 
facts, but does not determine what is and what it is sup-
posed to be like” [17]. When not conducted properly, even 
the best-designed study will do more harm than good.
I cannot categorically deny the need for randomized 
trials in cancer surgery. They are as needed as any other well-
planned and conducted clinical studies. Let us consider the 
way in which patients are prepared for surgery. It has been 
a standard procedure to bathe the patient the day before 
or immediately prior to surgery with the use of antiseptic 
soap, usually containing chlorhexidine. Metaanalyses of 
randomized trials have shown that the practice does not 
reduce the risk of infection [18]. However, will anyone de-
cide to skip bathing for that reason? A clinical study on one 
side, and clinical experience on the other will determine the 
choice of action.
“When no evidence achieves the expected level of sta-
tistical significance, anecdotal events can often give rise to 
an interesting hypothesis” [1].
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